StockpollyBeta
Get App
Popularity #3,466
INO · NASDAQ · Biotechnology

Inovio Pharmaceuticals (INO)

Develops DNA medicines and CELLECTRA devices, led by INO-3107 for recurrent respiratory papillomatosis.

$1.26
vs last close−0.03 (−2.33%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue000101010110
Gross profit000−10−10−10−1−10
362731322720252221172119
Research & development161721231913161413101411
10101199798,563877,8808
Selling & marketing000−10,19700000000
General & administrative1001110,2079098,563877,8808
Other expenses11000000−8,5550−1−7,8720
Operating income−36−27−31−33−27−20−25−23−21−17−22−19
22112150−2421213
Interest income22211111552000
Interest expense000000000000
Other non-operating income−2−3−1−1−2−1−5024−21−2−13
Income before tax−34−25−30−32−25−19−20−24−454−20−6
Net income from continuing operations−34−25−30−32−25−19−20−24−454−20−6
Net income−34−25−30−32−25−19−20−24−454−20−6
EPS, basic−$1.52−$1.10−$1.31−$1.19−$894.28−$0.70−$0.51−$0.61−$0.87$0.05−$0.28−$0.07
EPS, diluted−$1.52−$1.10−$1.31−$1.19−$894.28−$0.70−$725.11−$0.61−$0.87$0.05−$0.28−$0.07
Weighted average shares, basic222323272832393952696982
Weighted average shares, diluted222323272832393952696982
EBITDA−33−25−30−31−24−19−19−23−455−19−6
Depreciation & amortization101111111110
EBIT−34−25−30−32−25−19−20−24−454−20−6